Showing results (71-80 of 106) with videos related to
Sort By:
Pageof 11
Research Square|November 19, 2025
Phase II proof-of-concept study of durvalumab and cediranib with and without olaparib in recurrent ovarian cancerJung-Min Lee, Junya Tabata, Tzu-Ting Huang, et al.Frontiers in Pharmacology|April 17, 2023
Multi-omics analyses reveal ClpP activators disrupt essential mitochondrial pathways in triple-negative breast cancerEmily M J Fennell, Lucas J Aponte-Collazo, Wimal Pathmasiri, et al.Cancer Research Communications|November 17, 2022
Mitochondrial Matrix Protease ClpP Agonists Inhibit Cancer Stem Cell Function in Breast Cancer Cells by Disrupting Mitochondrial HomeostasisYoshimi Endo Greer, Lidia Hernandez, Emily M J Fennell, et al.Journal for Immunotherapy of Cancer|July 27, 2019
A phase I study of the PD-L1 inhibitor, durvalumab, in combination with a PARP inhibitor, olaparib, and a VEGFR1-3 inhibitor, cediranib, in recurrent women's cancers with biomarker analysesAlexandra S Zimmer, Erin Nichols, Ashley Cimino-Mathews, et al.Oncotarget|November 8, 2017
Phase I/Ib study of olaparib and carboplatin in women with triple negative breast cancerJung-Min Lee, John L Hays, Victoria L Chiou, et al.The Lancet. Oncology|January 24, 2018
Prexasertib, a cell cycle checkpoint kinase 1 and 2 inhibitor, in BRCA wild-type recurrent high-grade serous ovarian cancer: a first-in-class proof-of-concept phase 2 studyJung-Min Lee, Jayakumar Nair, Alexandra Zimmer, et al.The Oncologist|June 6, 2023
A Single-Arm, Open-Label Phase II Study of ONC201 in Recurrent/Refractory Metastatic Breast Cancer and Advanced Endometrial CarcinomaSarah L P Atkins, Yoshimi Endo Greer, Sarah Jenkins, et al.American Journal of Clinical Pathology|February 12, 2024
Characterization of T-/natural killer cell lymphoproliferative neoplasms associated with systemic, chronic, active Epstein-Barr virus in adults: A report of 5 cases in a Western populationCarlos Murga-Zamalloa, Michael Brandon Stone, Marc G Gutierrez, et al.Nature Communications|March 17, 2026
Durvalumab and cediranib with and without olaparib in recurrent ovarian cancer: a phase II proof-of-concept studyJunya Tabata, Tzu-Ting Huang, Elena Giudice, et al.Nature Communications|March 30, 2024
The CHK1 inhibitor prexasertib in BRCA wild-type platinum-resistant recurrent high-grade serous ovarian carcinoma: a phase 2 trialElena Giudice, Tzu-Ting Huang, Jayakumar R Nair, et al.Pageof 11